These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28950269)

  • 1. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
    Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
    González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
    Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
    Cho H; Yoon DH; Lee JB; Kim SY; Moon JH; Do YR; Lee JH; Park Y; Lee HS; Eom HS; Shin HJ; Min CK; Kim JS; Jo JC; Kang HJ; Mun YC; Lee WS; Lee JJ; Suh C; Kim K;
    Am J Hematol; 2017 Dec; 92(12):1280-1286. PubMed ID: 28833417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
    Scott EC; Hari P; Kumar S; Fraser R; Davila O; Shah N; Gale RP; Diaz MA; Agrawal V; Cornell RF; Ganguly S; Akpek G; Freytes C; Hashmi S; Malek E; Kamble RT; Lazarus H; Solh M; Usmani SZ; Kanate AS; Saad A; Chhabra S; Gergis U; Cerny J; Kyle RA; Lee C; Kindwall-Keller T; Assal A; Hildebrandt GC; Holmberg L; Maziarz RT; Nishihori T; Seo S; Kumar S; Mark T; D'Souza A
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2443-2449. PubMed ID: 30142419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
    Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
    Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
    Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
    Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
    Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
    Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
    Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
    Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
    Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
    Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
    Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
    Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
    Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
    [No Abstract]   [Full Text] [Related]  

  • 17. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
    Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
    Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: Experience of an institute in limited resource setting.
    Jacob LA; Suresh Babu MC; Lakshmaiah KC; Babu KG; Lokanatha D; Rajeev LK; Lokesh KN; Rudresha AH; Agarwal A; Garg S
    Indian J Cancer; 2017; 54(1):340-342. PubMed ID: 29199718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
    Kuroda J; Shimura Y; Ohta K; Tanaka H; Shibayama H; Kosugi S; Fuchida S; Kobayashi M; Kaneko H; Uoshima N; Ishii K; Nomura S; Taniwaki M; Takaori-Kondo A; Shimazaki C; Tsudo M; Hino M; Matsumura I; Kanakura Y;
    Int J Hematol; 2014 Apr; 99(4):441-9. PubMed ID: 24584872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.